Fresenius SE
Home
|
Contacts
|
Imprint
|
Sitemap
|
Glossary
|
Guided Tour
|
German
WHO WE ARE
The Health Care Group
Products and Services
Facts and Figures
Locations Worldwide
Management Board
Supervisory Board
Environment
History
Frequently Asked Questions
Contacts
INVESTOR RELATIONS
The Fresenius Shares
Bonds and Rating
News
Financial Reports
Presentations
Corporate Governance
Facts and Figures
Annual General Meeting
Financial Calendar and Conferences
Information & Order Service
Frequently Asked Questions
Contacts
Stock Dictionary
PRESS
Press Releases
Photo Service
Audio/Video Service
TV Service
Calendar
Facts and Figures
Contacts
HEALTHCARE
Fresenius Medical Care
Dialysis at a Clinic or at Home
Hemodialysis
Peritoneal Dialysis
Supplemental Drugs
Other Extracorporeal Systems
Fresenius Kabi
Infusion Therapy
Clinical Nutrition
Home Care
Fresenius Helios
Care Structure
Medical Quality
Knowledge Management
HELIOS Highlights
Fresenius Vamed
Fresenius Biotech
Transplantation
Cancer Therapy
Cell and Gene Therapy
All Segments
CAREER
Why Fresenius?
Who we are looking for
Job Market
Online application
Career Fairs
Personnel in Numbers
Around our Plants
Contacts
SEARCH
Press Releases
All
Business & Finance
Quarterly Results
Medicine & Research
2008
2007
2006
2005
2004
2003
2002
Order Service
Photo Service
Audio/Video Service
TV Service
Calendar
Facts and Figures
Contacts
Fresenius Kabi to acquire APP Pharmaceuticals
Please click here for Press Releases, Investor News and additional information.
>>>
Share Price
Next Event
02.12.2008
Capital Market Day Fresenius Helios and Fresenius Vamed
>>>
Further events
>>>
To view PDF-files you need Adobe Reader. You can download this software free of charge.
Medicine & Research - 2005
29.06.2005
Clinical Studies indicate Better Survival and Protection of the Peritoneal Membrane using an Innovative Peritoneal Dialysis Fluid
Text as PDF-file
06.06.2005
Special treatment for patients with chronic kidney failure indicates significantly improved patient survival
Text as PDF-file
18.05.2005
ASCO-Meeting: Fresenius Biotech presents clinical trial results of new antibodies at the world’s largest cancer convention
Text as PDF-file
17.03.2005
Fresenius Kabi recognized by Frost & Sullivan for Competitive Strategy Leadership in Clinical Nutrition
Text as PDF-file
06.01.2005
Immune Suppressive ATG-Fresenius S Receives Fast Track Status in the U.S. - First Patient Recruited in Clinical Trial
Text as PDF-file
Home
>
Press
>
Press Releases
>
Medicine & Research
>
2005